Literature DB >> 15748206

Lipid based particulate formulations for the delivery of antigen.

Melissa J Copland1, Thomas Rades, Nigel M Davies, Margaret A Baird.   

Abstract

Particulate adjuvant systems are largely classified according to their functional characteristics, such as the nature of the typical immune response they induce, or their perceived mode of action. From a formulation science perspective, it is practical to classify antigen delivery systems according to the physical nature of the formulations. This article discusses lipid based particulate systems, grouped according to the nature of their predominant lipid constituent.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15748206     DOI： 10.1111/j.1440-1711.2005.01315.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN： 0818-9641            Impact factor:   5.126


  26 in total

Review 1.  Nanoparticulate systems for growth factor delivery.

Authors:  Sufeng Zhang; Hasan Uludağ
Journal:  Pharm Res       Date:  2009-05-05       Impact factor: 4.200

2.  In vitro responses of human peripheral blood mononuclear cells to whole-cell, particulate and soluble extracts of Leishmania promastigotes.

Authors:  E Telino; P M De Luca; D C S Matos; R B Azeredo-Coutinho; M N Meirelles; F Conceição-Silva; A Schubach; S C F Mendonça
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

3.  Delivery of foreign antigens by engineered outer membrane vesicle vaccines.

Authors:  David J Chen; Nikolaus Osterrieder; Stephan M Metzger; Elizabeth Buckles; Anne M Doody; Matthew P DeLisa; David Putnam
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-27       Impact factor: 11.205

Review 4.  Nanovaccines for cancer immunotherapy.

Authors:  Yu Zhang; Shuibin Lin; Xiang-Yang Wang; Guizhi Zhu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-06-06

Review 5.  The role of nanotechnology in the treatment of viral infections.

Authors:  Lavanya Singh; Hendrik G Kruger; Glenn E M Maguire; Thavendran Govender; Raveen Parboosing
Journal:  Ther Adv Infect Dis       Date:  2017-07-05

Review 6.  Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.

Authors:  Tewodros Mamo; E Ashley Moseman; Nagesh Kolishetti; Carolina Salvador-Morales; Jinjun Shi; Daniel R Kuritzkes; Robert Langer; Ulrich von Andrian; Omid C Farokhzad
Journal:  Nanomedicine (Lond)       Date:  2010-02       Impact factor: 5.307

7.  Multivalent porous silicon nanoparticles enhance the immune activation potency of agonistic CD40 antibody.

Authors:  Luo Gu; Laura E Ruff; Zhengtao Qin; Maripat Corr; Stephen M Hedrick; Michael J Sailor
Journal:  Adv Mater       Date:  2012-06-12       Impact factor: 30.849

Review 8.  Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines.

Authors:  Stacey L Demento; Alyssa L Siefert; Arunima Bandyopadhyay; Fiona A Sharp; Tarek M Fahmy
Journal:  Trends Biotechnol       Date:  2011-04-02       Impact factor: 19.536

9.  C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice.

Authors:  Delaram Doroud; Farnaz Zahedifard; Alireza Vatanara; Yasaman Taslimi; Rouholah Vahabpour; Fatemeh Torkashvand; Behrooz Vaziri; Abdolhossein Rouholamini Najafabadi; Sima Rafati
Journal:  PLoS Negl Trop Dis       Date:  2011-07-12

10.  Comparison of in vivo Adjuvanticity of Liposomal PO CpG ODN with Liposomal PS CpG ODN: Soluble Leishmania Antigens as a Model.

Authors:  Ensieh Golali; Mahmoud Reza Jaafari; Ali Khamesipour; Azam Abbasi; Zahra Saberi; Ali Badiee
Journal:  Iran J Basic Med Sci       Date:  2012-09       Impact factor: 2.699
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.